The evidence balance on compounded GLP-1 safety The National Center for Complementary and Integrative Health (NCCIH), the FDA, and multiple medical societies - including the American Diabetes Association - have published guidance noting that compounded GLP-1 preparations carry additional safety uncertainty compared to FDA-approved finished products
So, providers should evaluate these findings alongside those other considerations as they assess which option might be best for their individual patients. Rodriguez said their research group plans to examine more trends with semaglutide, tirzepatide and other medications in the future, including outcomes for treating other conditions, barriers to equitable access, health outcomes following medication discontinuation and trends for restarting a medication
This interaction is most critical during the dose escalation phases
Mechanism: Both reduce appetite and slow gastric emptying
Once weekly tirzepatide and treatment exposure of up to 104 weeks (median follow-up of 55 weeks) resulted in an HR of 0.81 (97.85% CI, 0.521.26) for the pooled tirzepatide group compared to the pooled comparator group from 116 composite MACE-4 endpoints (pooled tirzepatide: 60 (1.37 per 100 person-years) and pooled comparator: 56 (1.60 per 100 person-years)) and, therefore, met the criteria that treatment with tirzepatide was not associated with excess cardiovascular risk and initiated early close-out of SURPASS-4
